Zinc Oxide Patches Are a Highly Effective Treatment for Chronic Prurigo: A Randomized Split-Body Study.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Established treatment options are often unsatisfying.

Patients often report rapid relief of symptoms when using topical occlusive zinc oxide patches (ZOP).

Who Took Part

According to the abstract, 22 participants were involved.

In this randomized controlled split-body crossover study, 22 participants were analyzed, receiving three treatments sequentially: ZOP, topical betamethasone 17-valerate (topical glucocorticosteroids [TGCs]), and both ZOP and TGC combined (ZOP + TGC).

Outcomes were a count of active excoriated pruriginous lesions (APLs), itch, recurrence of APL, QoL, and treatment comfort.

How the Study Was Run

In design terms this was a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

In the crossover set-up each of the participants took both Vitamin D, K2, Magnesium and Zinc and the comparison in turn, acting as their own control.

Each intervention was applied to either the right or left side of the body for seven consecutive days.

They were assessed through photographs and questionnaires: modified Prurigo Activity and Severity Score, modified Itchy Quality of Life Questionnaire, and Therapy Comfort Score.

What Was Measured

PubMed files the paper under topics including Zinc Oxide, Prurigo, Quality of Life, Pruritus, Piperazines and Azabicyclo Compounds.

Author keywords: Chronic prurigo, Randomized split-body trial, Topical treatment and Zinc oxide patches.

What This Means in Plain Language

The paper is a randomized and crossover study of Vitamin D, K2, Magnesium and Zinc in 22 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Dermatology (Basel, Switzerland)), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.